|ANGEL Phase I Trial
||Phase I study to assess safety and feasibility of AdipoCell™
|IRB Studies (Degenerative Disc Disease, Macular Degeneration, COPD, Rheumatoid Arthritis)
||5 Clinical Sites
||Designed to test the safety and effectiveness of adipose derived stem cells (Adipocell) in various indications.
|MARVEL (Phase II/III Clinical Trial)
||MARVEL Part 1: 20 Patients (completed)
MARVEL Part 2: 133 Patients
||Up to 35 sites in the United States
||Designed to be a double blind, randomized, placebo controlled multi-center trial to evaluate the safety and efficacy of MyoCell® delivered via MyoStar®
||MyoCell® implantation procedure completed on first patient in October 2007. MARVEL part 1 data on the first 20 patients analyzed and presented at the Heart Failure Society of America (HFSA) Meeting in 2009. Data displayed overall positive clinical result
|MYOHEART (Phase I Clinical Trial)
||Five sites in the United States
||Trials have been designed to test the safety and efficacy of MyoCell in treating patients with severe, chronic damage to the heart.
||Trial commenced in 2003; treatment of all 20 patients completed in October 2006; final twelve-month data presented in January 2008.
|REGEN (Phase I Clinical Trial)
||3 Sites in US
||Designed to test the safety and effectiveness of a composition of muscle stem cells that have been gene-modified to induce a greater than usual release of the SDF-1 protein
||Approval received in July 2009 from the FDA to move forward with the trail.